BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the second quarter and six months ended June 30, 2007. In addition, the company provided an update on its broad pipeline of antibody-based therapies for the treatment of unmet needs in cancer.
